ArticleBone marrow transplantation2024
Transplant conditioning with bortezomib, thalidomide, and melphalan and intensive 2 year post-transplant therapy for multiple myeloma in older patients.
Christopher Strouse, Sarah L Mott, Brian J Smith, Margarida Magalhaes-Silverman, Umar Farooq, Fenghuang Zhan, Yogesh Jethava, Guido Tricot
Abstract readLetter
In one paragraphArticle in Bone marrow transplantation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
8 authors.
Christopher StrouseDivision of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa, Iowa City, IA, USA. Christopher-strouse@uiowa.edu.ORCID 0000-0003-4964-167X Sarah L MottHolden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA.
Brian J SmithHolden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA.
Margarida Magalhaes-SilvermanDivision of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa, Iowa City, IA, USA.
Umar FarooqDivision of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa, Iowa City, IA, USA.
Fenghuang ZhanWinthrop P. Rockefeller Cancer Institute, University of Arkansas Medical Center, Little Rock, AK, USA.
Yogesh JethavaIndiana Blood & Marrow Transplant, Indianapolis, IN, USA.
Guido TricotWinthrop P. Rockefeller Cancer Institute, University of Arkansas Medical Center, Little Rock, AK, USA.
Funding
Prevention of MGUS Progression to MM by Modulating the Bone Marrow MicroenvironmentU54CA272691 · NCI · CHILDREN'S MERCY HOSP (KANSAS CITY, MO) · PI Yong Li · 2023 to 2026
$6.1MTowards a better understanding of the critical role and therapeutic potential of drug resistant genes in multiple myelomaR01CA236814 · NCI · UNIV OF ARKANSAS FOR MED SCIS · PI FENGHUANG ZHAN · 2020 to 2026
$2.5MAutomated Problem and Allergy Lists Enrichment Based on High Accuracy Information Extraction from the Electronic Health RecordR42CA180190 · NCI · CLINACUITY,INC. · PI MEYSTRE, STEPHANE · 2016 to 2017
$1.5MAutomated Dynamic Lists for Efficient Electronic Health Record ManagementR41CA180190 · NCI · CLINACUITY,INC. · PI MEYSTRE, STEPHANE · 2013 to 2014
$422kNCI NIH HHS R01 CA236814NCI NIH HHS R41 CA180190NCI NIH HHS R42 CA180190NCI NIH HHS U54 CA272691
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
Multiple MyelomaAgedAntineoplastic Combined Chemotherapy ProtocolsBortezomibDexamethasoneHumansMelphalanPyrazinesThalidomideBortezomibDexamethasoneMelphalanPyrazinesThalidomide
Identifiers
PMID37816907
PMCPMC10781621
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390